FDA 483 - Lanzhou Foci Pharmaceutical Co., Ltd. - March 20, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Lanzhou Foci Pharmaceutical Co., Ltd. in Lanzhou, China, a dietary supplement manufacturer, revealed multiple significant deficiencies. The firm failed to establish product specifications for contaminants, use scientifically valid testing methods, verify dietary ingredient identity, and test components for impurities. Additionally, the inspection found inadequate equipment cleaning and maintenance, pest control issues, and plumbing cross-connections, indicating severe lapses in manufacturing controls.
ID · a2c0210d-96a1-42f8-91ae-a08a2d950f23